The Cross Cancer Insitute in Edmonton is current recruiting first-line metastatic colorectal cancer patients to participate in a randomized, phase II study. Comparing the effects of bevacizumab/mFOLFOX6 versus bevacizumab/FOLFRI via repeated intravenous influsions, the primary outcome of the trial is progression-free survival.
To learn more about the trial, including the full inclusion and exclusion criteria, click here.
No comments:
Post a Comment